Independent. Not owned by or funded by any pharmaceutical manufacturer.
Evidence-sourced · medically-reviewed where indicated
Patient-reported outcomes

The Open Research Exchange: what it was, and where its instruments are now

The Open Research Exchange was a platform for building health questionnaires with patients. Journal articles still link to it. This page explains what it was and where to find the work it hosted.

We are not PatientsLikeMe. GLP-1 Healthcare is an independent publisher on GLP-1 medications and has no connection with PatientsLikeMe or the Open Research Exchange’s researchers. Nothing here is published by or for them.

Evidence-sourced
Written and fact-checked to our published editorial standards.Last updated 2026-11-12. Every clinical claim on this page is sourced to a named primary authority, listed at the foot of the page — see how we research, source, and correct our work.

Direct answer

What you need to know

The Open Research Exchange (ORE) was PatientsLikeMe’s platform for developing and sharing patient-reported outcome measures, built with support from the Robert Wood Johnson Foundation. When we checked on 12 November 2026, its site’s footer still read “© 2005-2019” and the instrument page that journal articles cite returned 404 Not Found. The best-documented instrument connected to it, the MS-TAQ, is described in full in an open-access 2011 paper.

Key takeaways

  • ORE described itself as an open platform for developing, validating and sharing health outcome measures.
  • It said measures built on it would be licensed so others could use and extend them at no cost.
  • The library page cited for the Polish version of the MS-TAQ returned 404 Not Found on 12 November 2026, and has no archived copy.
  • The MS-TAQ has 30 questions in 3 subscales: Barriers, Side Effects, Coping Strategies.

Important limitation: We can describe only what ORE’s own pages and the published papers say. We have no access to its instrument library or its records.

Next action: If you need the MS-TAQ itself, start from its published development paper and contact its authors about the current terms of use.

Primary sources: ORE FAQ (archived), JMIR 2011 (PMID 21266318)

An independent account. Not affiliated with, endorsed by or published for PatientsLikeMe.

What the Open Research Exchange was

Its FAQ described ORE as “an open platform for developing, validating and sharing health outcome measures that better reflect patients’ experiences with a disease”. Its About page credited the funding: “With support from the Robert Wood Johnson Foundation, we’re now building the Open Research Exchange (ORE)”. And its FAQ set out the licensing promise that made it unusual: “Measures developed on the platform will be licensed under terms that allow others to use and extend them at no cost”.

Put plainly, the aim was questionnaires shaped by what patients experience rather than only by what researchers think to ask. On 12 November 2026, the site at openresearchexchange.com still served its home, About and FAQ pages, under a footer reading “© 2005-2019 PatientsLikeMe”.

The instrument library, and the MS-TAQ

ORE’s site included an instrument library. At least two peer-reviewed studies of medication adherence in multiple sclerosis, published in 2018 and 2022, link in their reference lists to a library page for the Polish version of the MS-TAQ. That page, /public/library/instruments/30/overview, returned 404 Not Found when we checked on 12 November 2026.

The instrument itself is documented. The Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ) was developed in a study led from PatientsLikeMe’s research team, from a literature review and from discussions between patients in its online community, then refined by cognitive debriefing. It has 30 questions in 3 subscales (Barriers, Side Effects, Coping Strategies), and was tested in an online survey that 431 of 1,209 invited patients completed. The development paper is open access in the Journal of Medical Internet Research.

Why this page is on a GLP-1 site

We cover how GLP-1 trials measured what patients felt, not only what they weighed, and that depends on questionnaires built the way ORE set out to build them. Our review of what participants in GLP-1 trials reported about pain, function and quality of life covers the questionnaires those trials used, who validated them, and who paid.

Sources

Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.

  1. Open Research Exchange: FAQ (archived copy)PatientsLikeMeSupports: ORE's own description of its purpose and of the licensing of measures built on it.
  2. Open Research Exchange: About us (archived copy)PatientsLikeMeSupports: The Robert Wood Johnson Foundation's support for building ORE.
  3. Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)Journal of Medical Internet Research 2011;13(1):e12 (Wicks et al.)Supports: How the MS-TAQ was developed, its structure, and the survey used to test it.
  4. Adherence to disease-modifying therapies in patients with multiple sclerosisPatient Preference and Adherence 2018;12:1557–1566 (Kołtuniuk et al.)Supports: Cites the Polish version of the MS-TAQ at ORE's instrument library.
  5. The Quality of Life and Medication Adherence in Patients with Multiple Sclerosis—Cross-Sectional StudyInternational Journal of Environmental Research and Public Health 2022;19(21) (Kołtuniuk et al.)Supports: Cites the Polish version of the MS-TAQ at ORE's instrument library.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.